MAPT and Alzheimer disease: Active Aβ42 immunity in AD patients leads to Aβ removal, associated with a decrease in phosphorylated Tau, long-term downregulation of inflammation, a decrease in the number of neurons, and an abnormal decrease in neuritis (Nicoll et al., 2006; Paquet et al., 2018).